Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research

Roth, Arnaud; Fazio, Nicola; Stupp, Roger; Falk, Stephen; Bernhard, Jürg; Saletti, Piercarlo; Köberle, Dieter; Borner, Markus M; Rufibach, Kaspar; Maibach, Rudolf; Wernli, Martin; Leslie, Martin; Glynne-Jones, Robert; Widmer, Lukas; Seymour, Matthew; de Braud, Filippo

doi:10.1200/JCO.2006.08.0135

Scientific article

English

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research

ContributorsRoth, Arnaud; Fazio, Nicola; Stupp, Roger; Falk, Stephen; Bernhard, Jürg; Saletti, Piercarlo; Köberle, Dieter; Borner, Markus M; Rufibach, Kaspar; Maibach, Rudolf; Wernli, Martin; Leslie, Martin; Glynne-Jones, Robert; Widmer, Lukas; Seymour, Matthew; de Braud, Filippo

Published inJournal of clinical oncology, vol. 25, no. 22, p. 3217-3223

Publication date2007

Abstract

This randomized phase II trial evaluated two docetaxel-based regimens to see which would be most promising according to overall response rate (ORR) for comparison in a phase III trial with epirubicin-cisplatin-fluorouracil (ECF) as first-line advanced gastric cancer therapy.

Keywords

Adenocarcinoma/drug therapy/pathology
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
Cisplatin/administration & dosage
Epirubicin/administration & dosage
Female
Fluorouracil/administration & dosage
Humans
Male
Middle Aged
Quality of Life
Stomach Neoplasms/drug therapy/pathology
Taxoids/administration & dosage
Treatment Outcome

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Groupe Roth Arnaud (oncologie) (285)

Citation (ISO format)

ROTH, Arnaud et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. In: Journal of clinical oncology, 2007, vol. 25, n° 22, p. 3217–3223. doi: 10.1200/JCO.2006.08.0135

Article (Published version)

Identifiers

PID : unige:35207
DOI : 10.1200/JCO.2006.08.0135
PMID : 17664469

Journal ISSN0732-183X

586views

0downloads

Creation28/03/2014 10:54:00

First validation28/03/2014 10:54:00

Update14/03/2023 21:04:24

Status update14/03/2023 21:04:23

Last indexation30/10/2024 16:40:22

Archive ouverte UNIGE

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research

This randomized phase II trial evaluated two docetaxel-based regimens to see which would be most promising according to overall response rate (ORR) for comparison in a phase III trial with epirubicin-cisplatin-fluorouracil (ECF) as first-line advanced gastric cancer therapy.

Technical informations